Oncology

Approvals for oncology drugs is around 5% - less than half compared to other treatment areas. The rate of failure is increasing, especially beyond Phase II trials.
New regulatory requirements for the development of regenerative medicine in oncology demands stakeholders to be even more conscious of safety throughout the development process.
Recently, drug development in Asia has become increasingly active. Preparedness to differences between Asian countries is critical to development.

1：Providing full service consultations - from the initial stages of development all the way to regulatory authority submission.

2：CRAs specialized in oncology are assigned to the trials to increase the probability of a successful trial.

Led by experts with over 20 years of working experience in clinical trials for oncology, over 90% of our projects have achieved milestones in oncology.

3：Full scope of clinical trials across Asia.

4：We have received superior reviews globally for its highly accurate feasibility studies capable only through its proprietary network.

5：Oncology focused Employee Training

We have implemented a one-of-a-kind certification program for developing Oncology specialists under the guidance of （Dr. Nagahiro Saijo (globally recognized KOL).）CRAs who have obtained Remedy’s specialized certifications are assigned to clinical trials.
Our MSLs are highly qualified with extensive on-site experience and expertise in Oncology.